DETROIT -- Technology to restore vision through the use of a component of green algae developed by Dr. Zhou-Han Pan, professor and scientific director of the Ligon Research Center of Vision at the Kresge Eye Institute at Wayne State University, and licensed to RetroSense Therapeutics, a biotechnology company dedicated to developing gene therapy approaches to vision restoration, announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S. patent application (No. 12/299,574). The notice broadly covers methods of restoring visual responses with a variety of optogenetic compounds.
The application includes claims covering methods of restoring visual responses by delivery to retinal neurons any of a number of channelrhodopsin variants, as well as halorhodopsin. The two molecules have been studied extensively and published on as means of vision restoration in retinal degenerative conditions such as retinitis pigmentosa and dry age-related macular degeneration.
The approved patent application is part of the "Pan" patent family, which stems from the novel research of Pan and others at Wayne State University and Salus University, designed to restore vision in retinal degenerative conditions. Several Pan patent applications are part of RetroSense's intellectual property estate, which focuses on optogenetic gene therapies and complementary devices for vision restoration.
"We are pleased that the U.S. Patent Office has allowed this patent application, which will substantively expand the coverage of RetroSense's intellectual property estate," said Sean Ainsworth, chief executive officer of RetroSense. "Our IP position provides broad protection. RetroSense continues to develop novel intellectual property in the area of optogenetics. Accordingly, we plan to continue to extend our basic patent protections on our technologies. We have also maintained an ongoing strategy to consolidate key intellectual property required to develop and commercialize optogenetics to restore visual responses."
The newly allowed U.S. patent application covers methods of increasing visually evoked potentials by delivering to retinal neurons one or more of the following molecules:
- Channelrhodopsin-2 (and a multitude of variants thereof)
Claims also explicitly cover targeting these molecules with cell-type specific promoters, including mGluR6 (Grm6).
Following a Notice of Allowance, the process resulting in final issuance of a patent involves several administrative steps that are typically completed within a year.
Pan has received funding to support his research from the National Eye Institute of the National Institutes of Health (EY004068 and EY017130), The Foundation for Fighting Blindness, and Hope for Vision.
About Wayne State University
Wayne State University is one of the nation's pre-eminent public research universities in an urban setting. Through its multidisciplinary approach to research and education, and its ongoing collaboration with government, industry and other institutions, the university seeks to enhance economic growth and improve the quality of life in the city of Detroit, state of Michigan and throughout the world. For more information about research at Wayne State University, visit http://www.
About RetroSense Therapeutics
RetroSense Therapeutics is a biotechnology company developing game-changing gene therapies designed to restore vision in patients suffering from blindness due to retinitis pigmentosa (RP) and advanced dry age-related macular degeneration (advanced dry-AMD). There are currently no FDA approved drugs to improve or restore vision in patients with these retinal degenerative conditions. RetroSense is led by a team of seasoned veterans with deep experience in taking products from the discovery stage through to the clinic. For more information about RetroSense, visit http://www.